[Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
OBJECTIVE
We tested whether immunohistochemical detection of oestrogen and progesterone receptor (ER, PR), the oestrogen-dependent protein pS2, the growth hormone receptors p 185neu and EGF-R, the tumour suppressor protein p53, the tissue proteases Cathepsin D and Urokinase, and the proliferation marker PCNA are of prognostic relevance in breast cancer patients.


METHODS
Expression of the proteins listed above was evaluated in formalin-fixed and paraffin-embedded sections of 311 primary breast cancer specimens using modified Avidin-Biotin-Complex methods. Results were correlated to clinical and morphological parameters (age, menopausal status, nodal status, tumour size, tumour grade), and clinical course of disease (complete follow-up in 301 women, median observation time 62 months) utilising univariate and multivariate statistical analyses.


RESULTS
If univariate analyses and multivariate regression analyses according to the Cox-model were applied, only Cathepsin D correlated to an elevated risk for recurrence in nodally negative patients (n = 135). In nodally positive women (n = 161), increasing tumour size, tumour grade, lack of ER and PR, expression of p185neu, p53, and PCNA indicated a significantly increased relative risk.


CONCLUSIONS
Immunohistochemistry allows the detection of parameters which may indicate prognosis in subgroup of breast cancer patients.
Göhring
U J
UJ
Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitt Köln.
Scharl
A
A
Ahr
A
A
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D001940:Breast / Q000473:pathology; D001943:Breast Neoplasms / Q000473:pathology* / Q000628:therapy; D002402:Cathepsin D / Q000032:analysis; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis; D011506:Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D000071163:Trefoil Factor-1; D016159:Tumor Suppressor Protein p53 / Q000032:analysis; D025521:Tumor Suppressor Proteins; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis
D014408:Biomarkers, Tumor; D002402:Cathepsin D; D066246:ErbB Receptors; D009363:Neoplasm Proteins; D018809:Proliferating Cell Nuclear Antigen; D011506:Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D000071163:Trefoil Factor-1; D016159:Tumor Suppressor Protein p53; D025521:Tumor Suppressor Proteins; D014568:Urokinase-Type Plasminogen Activator; C051838:TFF1 protein, human
Der Stellenwert der immunhistochemischen Bestimmung von Rezeptoren, Gewebsproteasen, Tumorsuppressorproteinen und Proliferationsmarkern als Prognoseindikatoren beim primären Mammakarzinom.